Condition: Resectable Hepatocellular Carcinoma With High Risk of Recurrence · Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
This is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.
This description comes directly from the study's public registry record.
Xinyu Bi · +86 (010)87787100 · beexy1971@163.com
Xiaowu Zhang · +86 (010)87788502 · zhangxiaowu767@163.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinese Academy of Medical Science | Beijing, Beijing Municipality, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| The First Hospital of China Medical University | Shenyang, Liaoning, China | Not Yet Recruiting |
| Shanxi Cancer Hospital | Taiyuan, Shanxi, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07239245